<!DOCTYPE html>
<html>
<head>
<meta charset="UTF-8">
<title>US Oncology Market Map ‚Äî RISA Labs</title>
<style>
  body { margin: 0; padding: 0; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; }
  #mindmap { width: 100vw; height: 100vh; }
  .markmap-node-text { font-size: 14px; }
</style>
<script src="https://cdn.jsdelivr.net/npm/d3@7"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.15.4"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-lib@0.15.4/dist/browser/index.js"></script>
</head>
<body><a href="https://risa-labs-inc.github.io/risa-market-intelligence/" style="position:fixed;top:12px;left:16px;z-index:999;color:#60a5fa;text-decoration:none;font-size:13px;font-weight:600;font-family:-apple-system,sans-serif">‚Üê Hub</a>
<svg id="mindmap"></svg>
<script>
const md = `
# US Oncology Ecosystem

## üè• Care Delivery
### NCI Comprehensive Cancer Centers
- MD Anderson
- Memorial Sloan Kettering
- Dana-Farber
- Fred Hutch
- Moffitt, City of Hope
- ~72 NCI-designated (53 comprehensive)
- Role: Research + clinical, trials, complex cases
- ‚≠ê RISA: Complex claim adjudication, denial mgmt

### Academic Medical Centers
- Stanford Cancer Center
- UCSF
- Johns Hopkins
- Mayo Clinic
- Cleveland Clinic
- Role: Teaching + research + tertiary referrals
- ‚≠ê RISA: Multi-dept charge capture, referral auth

### Community Oncology ‚≠ê PRIMARY TARGET
- Texas Oncology (550+ docs, 250+ sites)
- Florida Cancer Specialists
- Regional Cancer Care Associates
- **Delivers 60%+ of US cancer care**
- Ownership: Physician / PE / Health system
- Pain: Margins, denials, staffing, pathways
- ‚≠ê RISA: Prior auth, denial prevention, coding

### Hospital System Cancer Programs
- HCA Healthcare
- Providence
- Intermountain
- Northwell, CommonSpirit, Atrium
- Role: Integrated delivery, employed oncologists
- ‚≠ê RISA: Service line revenue, 340B compliance

### Oncology Networks / Management
- US Oncology (McKesson) ‚Äî 1,400+ physicians
- OneOncology (TPG) ‚Äî 600+ providers
- American Oncology Network (AON)
- Flatiron Health (Roche) ‚Äî EHR + RWD
- Role: GPO, practice mgmt, pathways, data
- ‚≠ê RISA: Platform deal = 100s of practices

## üí∞ Payers & Reimbursement
### Medicare / CMS
- Largest oncology payer (median age 66)
- Medicare FFS ‚Äî per service
- Medicare Advantage ‚Äî ~52% beneficiaries
- EOM (Enhancing Oncology Model) ‚Äî episodes
- ‚≠ê RISA: Denial reduction, EOM reporting, MA prior auth

### Commercial Payers
- UnitedHealthcare (owns Optum)
- Elevance / Anthem / BCBS
- Aetna (CVS Health)
- Cigna (Express Scripts)
- Mechanisms: Prior auth, step therapy, pathways
- ‚≠ê RISA: Prior auth automation, claims accuracy

### Medicaid
- 50 state programs + DC
- Managed Medicaid dominant
- Low reimbursement, complex eligibility
- ‚≠ê RISA: Eligibility verification, dual-eligible

### Specialty Pharmacy / PBMs
- CVS Caremark (#1)
- Express Scripts / Cigna (#2)
- Optum Rx / UHG (#3)
- Magellan Rx ‚Äî oncology focus
- Role: Oral oncolytics (~40% of pipeline)
- ‚≠ê RISA: Oral oncolytic prior auth, benefits

### Value-Based Care
- EOM (successor to OCM) ‚Äî CMS episodes
- Clinical Pathways: Via Oncology, NCCN, Elsevier
- Bundled Payments
- ‚≠ê RISA: EOM tracking, pathway adherence

## üíä Pharma & Biotech
### Large Pharma (~$220B+ global)
- Merck ‚Äî Keytruda ($25B, #1 drug)
- Roche/Genentech ‚Äî Tecentriq, Herceptin
- BMS ‚Äî Opdivo, Revlimid, Abecma
- AstraZeneca ‚Äî Tagrisso, Enhertu
- Pfizer ‚Äî Ibrance, Seagen (ADCs)
- Novartis ‚Äî Kisqali, Kymriah, Pluvicto
- Eli Lilly ‚Äî Verzenio, Retevmo
- J&J ‚Äî Darzalex, Carvykti
- AbbVie ‚Äî Imbruvica, Venclexta

### Emerging Biotech
- CAR-T: Kite/Gilead, Novartis, BMS, Legend ($300-500K)
- ADCs: Seagen/Pfizer, Daiichi Sankyo/AZ
- Bispecifics: Amgen, Roche, AbbVie
- Radiopharmaceuticals: Novartis, RayzeBio
- ‚≠ê RISA: Novel therapy billing, J-code mgmt

### Biosimilars
- Sandoz, Amgen, Teva, Coherus, Fresenius
- 15-40% savings on reference biologics
- ‚≠ê RISA: Biosimilar vs reference billing accuracy

### Specialty Distributors (Big 3)
- McKesson (#1 + US Oncology + GPO)
- Cencora / AmerisourceBergen (#2)
- Cardinal Health (#3 + nuclear)
- ‚≠ê RISA: Inventory-billing reconciliation, JW modifiers

## üß¨ Diagnostics & Precision Medicine
### Genomic Testing / CDx
- Foundation Medicine (Roche) ‚Äî FoundationOne
- Tempus ‚Äî xT, xF + AI insights
- Guardant Health ‚Äî liquid biopsy, Shield
- Myriad, NeoGenomics, Natera (Signatera)
- ‚≠ê RISA: Genomic test prior auth, LCD/NCD matching

### Pathology / Lab
- Quest Diagnostics
- Labcorp (+ Invitae)
- Hospital-based pathology
- Pain: Pathologist shortage, digitization

### Imaging
- Radiology Partners, RadNet, SimonMed
- PET/CT ‚Äî critical for staging
- ‚≠ê RISA: Imaging prior auth automation

### AI Diagnostics
- Paige AI ‚Äî FDA-cleared pathology
- Lunit ‚Äî radiology + pathology
- PathAI ‚Äî biopharma partnerships

## üî¨ Clinical Trials & Research
### NCI / NIH (~$7B annual)
- SWOG, ECOG-ACRIN, Alliance, NRG, COG
- ‚≠ê RISA: Trial billing compliance

### CROs
- IQVIA (largest)
- PPD / Thermo Fisher
- Parexel, Syneos Health

### Trial Matching
- Tempus ‚Äî AI from genomic + clinical
- TrialJectory, Massive Bio

### Real-World Data / Evidence
- Flatiron Health (Roche) ‚Äî 280+ clinics
- Tempus, ASCO CancerLinQ, Optum Labs
- Komodo Health
- ‚≠ê RISA: Claims enrichment for RWE

### Philanthropic Accelerators
- Parker Institute (PICI) ‚Äî $250M, immunotherapy
- Stand Up to Cancer, V Foundation, LLS

## üíª Technology & Data
### Oncology EHRs
- Flatiron OncoEMR ‚Äî community practices
- Varian ARIA ‚Äî radiation oncology
- Elekta MOSAIQ ‚Äî radiation oncology
- iKnowMed (McKesson) ‚Äî US Oncology
- Epic Beacon ‚Äî oncology module
- ‚≠ê RISA: EHR integration, automated charge capture

### RCM / Billing ‚≠ê‚≠ê CORE MARKET
- Waystar ‚Äî claims, prior auth (IPO 2024)
- Availity ‚Äî payer connectivity
- Change Healthcare (Optum) ‚Äî ~50% US claims
- R1 RCM, Coronis Health
- **Pain: 10-15%+ denial rates, 2-14 day auth delays**
- ‚≠ê RISA: Denial prevention, prior auth, coding, underpayment

### AI Companies in Oncology
- Clinical AI: Tempus, Flatiron, Paige, Lunit
- RCM AI: RISA Labs ‚≠ê, Waystar, Akasa, Infinx
- Patient Access: Notable Health, Qventus, Cedar
- ‚ö†Ô∏è Olive AI (shut down) ‚Äî cautionary tale

### Radiation Oncology Tech
- Varian/Siemens ‚Äî linacs, ARIA, Ethos
- Elekta ‚Äî Unity MR-Linac, MOSAIQ
- Accuray ‚Äî CyberKnife, TomoTherapy
- ‚≠ê RISA: Rad onc billing (most complex)

### Data Aggregators
- Definitive Healthcare, IQVIA
- Komodo Health, Truveta

## ‚öñÔ∏è Regulators & Guidelines
### FDA
- Drug approvals, breakthrough designations
- RTOR, Project Orbis
- New approvals ‚Üí new billing codes

### CMS
- Coverage: NCD/LCD
- Payment: OPPS, PFS, EOM, RO Model
- Quality: MIPS, APMs
- ‚≠ê CMS rules = billing complexity driver

### NCCN
- Gold-standard treatment guidelines
- Compendia ‚Üí off-label coverage basis
- Key for medical necessity / appeals

### ASCO / ESMO
- QOPI certification
- CancerLinQ data platform
- Guidelines, quality programs

### State Regulators
- Certificate of Need, oral parity (43+ states)
- Scope of practice, pharmacy compounding

### Accreditation
- Commission on Cancer (CoC/ACS)
- QOPI (ASCO), ACR, FACT (CAR-T)

## üéóÔ∏è Patients & Advocacy
### Patient Advocacy Orgs
- American Cancer Society (largest)
- LLS, Susan G. Komen, PanCAN
- LUNGevity, CRC Alliance, PCF

### Patient Navigation
- Nurse navigators (CoC requirement)
- Social workers, financial counselors
- ‚≠ê RISA: Automated financial counseling, benefits

### Patient Support Programs
- Manufacturer copay assistance
- Foundations: PAN, HealthWell, CancerCare
- Free drug / PAP programs
- ‚≠ê RISA: PSP enrollment, copay accumulator tracking

### Survivorship
- ~18M cancer survivors in US
- Long-term follow-up, late effects

## üìà Financial / Investment
### Private Equity
- TPG ‚Üí OneOncology
- Webster Equity, General Atlantic, GenStar
- Trend: Aggressive consolidation 2020-2025
- ‚≠ê PE platforms = sophisticated tech buyers

### Venture Capital
- Tempus ($6.1B IPO), Guardant ($3B+)
- Shift: Hype ‚Üí proof of ROI

### Public Markets
- Tempus AI (TEM), Guardant (GH)
- Exact Sciences (EXAS), Natera (NTRA)
- Waystar (WAY) ‚Äî RCM tech

## üîÑ Key Flows
### Money Flows
- Patient ‚Üí Provider (copay)
- Payer ‚Üí Provider (reimbursement)
- Provider ‚Üí Distributor ‚Üí Pharma (drugs)
- Pharma ‚Üí Payer (rebates)
- PE/VC ‚Üí Practices/Tech (investment)

### Data Flows
- Provider ‚Üí Clearinghouse ‚Üí Payer (claims)
- Provider ‚Üí EHR ‚Üí Aggregator (clinical)
- Diagnostics ‚Üí Provider (genomic reports)
- NCCN/FDA/CMS ‚Üí All (guidelines, policies)

### Prior Auth Flow (RISA Core)
- Identify need ‚Üí Check policy ‚Üí Submit auth
- Payer reviews ‚Üí Approve/Deny ‚Üí Appeal
- Treat ‚Üí Claim ‚Üí Adjudicate
- ‚≠ê RISA at: Policy, submission, appeal, coding

### Buy-and-Bill (Infused Drugs)
- Purchase drug ‚Üí Administer ‚Üí Bill J-code
- Reimburse ASP+6% ‚Üí Margin = Reimburse‚àíCost
- ‚≠ê RISA: J-code accuracy, waste (JW), NDC mapping
`;

const { Transformer } = window.markmap;
const transformer = new Transformer();
const { root } = transformer.transform(md);
const { Markmap } = window.markmap;
Markmap.create('#mindmap', {
  colorFreezeLevel: 2,
  duration: 300,
  maxWidth: 300,
  initialExpandLevel: 2,
  zoom: true,
  pan: true,
  fitRatio: 0.85
}, root);
</script>
</body>
</html>
